Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

NCT05004064 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Acalabrutinib
DRUG: Rituximab

Sponsor

University College, London

Collaborators

[object Object]